TPG Group Holdings (SBS) Advisors, Inc.
Institutional investor · Portfolio as of Q1 2015
Top Holdings37 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
1793264 | 196.1M | $8B | 40.4% | — | — | 2 qtrssince 2014-Q4 | Unchanged 0 |
12571 | 159.7M | $4.3B | 21.9% | — | — | 2 qtrssince 2014-Q4 | Unchanged 0 |
SABRE CORP | 131.8M | $3.2B | 16.2% | $17.75 | +20.79% | 2 qtrssince 2014-Q4 | Decreased 0 |
Surgical Care Affiliates, Inc. | 23.9M | $821.9M | 4.2% | — | — | 2 qtrssince 2014-Q4 | Unchanged 0 |
| 11.2M | $750.6M | 3.8% | — | — | 2 qtrssince 2014-Q4 | Unchanged 0 | |
LPL FINANCIAL HOLDINGS INC | 12.9M | $565.2M | 2.9% | $38.17 | -1.00% | 2 qtrssince 2014-Q4 | Unchanged 0 |
NORWEGIAN CRUISE LINE HOLDIN | 9.8M | $530.9M | 2.7% | $46.86 | +13.70% | 2 qtrssince 2014-Q4 | Decreased 0 |
| 23.7M | $410.6M | 2.1% | — | — | 2 qtrssince 2014-Q4 | Unchanged 0 | |
| 8.7M | $157.5M | 0.8% | — | — | 2 qtrssince 2014-Q4 | Unchanged 0 | |
AV Homes Inc. | 9.2M | $147.1M | 0.7% | — | — | 2 qtrssince 2014-Q4 | Unchanged 0 |
Ultragenyx Pharmaceutical, Inc. | 1.6M | $99.1M | 0.5% | $44.04 | +38.40% | 2 qtrssince 2014-Q4 | Decreased 0 |
Otonomy, Inc. | 2.2M | $76.4M | 0.4% | — | — | 2 qtrssince 2014-Q4 | Unchanged 0 |
ALDER BIOPHARMACEUTICALS INC | 2.5M | $71.8M | 0.4% | — | — | 1 qtr | New 50 |
AERIE PHARMACEUTICALS INC | 1.8M | $57.6M | 0.3% | — | — | 2 qtrssince 2014-Q4 | Decreased 0 |
Sixth Street Specialty Lending, | 3.2M | $55.7M | 0.3% | $5.45 | +5.32% | 2 qtrssince 2014-Q4 | Unchanged 0 |
VERINT SYSTEMS INC | 648,540 | $40.2M | 0.2% | — | — | 2 qtrssince 2014-Q4 | Increased 46 |
| 1.5M | $39.8M | 0.2% | — | — | 2 qtrssince 2014-Q4 | Increased 53 | |
INTERACTIVE BROKERS GRO-CL A | 1.2M | $39.6M | 0.2% | $6.95 | +13.05% | 2 qtrssince 2014-Q4 | Increased 43 |
| 111,658 | $33.2M | 0.2% | — | — | 2 qtrssince 2014-Q4 | Increased 47 | |
Tandem Diabetes Care, Inc. | 2.5M | $31.5M | 0.2% | — | — | — | — |
TPG Group Holdings (SBS) Advisors, Inc. manages $19.8B across 37 positions as of Q1 2015. Top holdings: FSL (40.4%), IMS (21.9%), SABR (16.2%). Fund DNA: Balanced Allocator.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer